News

CURE1h
FDA Approves Brukinsa Tablet For Various Blood Cancers
FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as ...
EU Drug Regulator Finds ‘Very Rare’ Ozempic Link to Vision Loss
Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...
National Health Executive1d
Oxford vaccine against deadly Nipah virus granted European Medicines Agency PRIME designation
The University of Oxford’s vaccine to protect people from deadly Nipah virus has been granted support from the PRIority MEdicine ...
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...
Consilium8d
The pharma package: new EU rules on medicines
The purpose of the pharma package is to revise the current rules on medicines to make them more accessible to patients while ...
Medical Dialogues2d
Diabetes and Weight-Loss Drug Semaglutide Linked to Rare Eye Condition: European Medical Agency
Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines, confirming a ...
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...